We present our institution's protocol for evaluating and transplanting thoracic organs from COVID-19 positive donors and report the outcomes to date. Hearts from donors testing positive for COVID-19 on any test were eligible for transplantation at our institution provided the donor exhibited no evidence of hypercoagulability or COVID-19 induced hyperinflammatory state during terminal hospitalization. Lungs were eligible if the donor first tested PCR positive on nasopharyngeal swab (NPS) for COVID-19 > 20 days prior to procurement and had a negative lower respiratory tract specimen. We performed 14 thoracic transplants in 13 recipients using organs from COVID-19 positive donors. None of the recipients or healthcare members acquired COVID-19. No recipients suffered unexpected acute rejection. Patient survival is 92% to date, with graft survival 93%. The use of hearts from COVID-19 positive donors may be safe and effective. Transplantation of lungs is unresolved but may be cautiously pursued under the restricted circumstances.

我们介绍了我们机构评估和移植 COVID-19 阳性供体胸器官的方案，并报告了迄今为止的结果。如果捐赠者在临终住院期间没有表现出高凝状态或 COVID-19 诱发的过度炎症状态的证据，则在任何测试中 COVID-19 检测呈阳性的捐赠者的心脏都有资格在我们的机构进行移植。如果捐赠者在采购前 20 天以上的鼻咽拭子 (NPS) 检测 PCR 呈 COVID-19 阳性且下呼吸道标本呈阴性，则肺符合条件。我们使用 COVID-19 阳性供体的器官对 13 名接受者进行了 14 次胸部移植。接受者或医疗保健成员均未感染 COVID-19。没有接受者遭受意外的急性排斥反应。迄今为止，患者存活率为 92%，移植物存活率为 93%。使用来自 COVID-19 阳性捐献者的心脏可能是安全有效的。肺移植尚未解决，但在受限情况下可能会谨慎进行。